Onkológia 6/2010

Faslodex 500 and new treatment options

One of the principal therapeutic procedures in metastatic breast cancer is hormonal therapy. In patients with positive oestrogen receptors, it should be considered as first-line therapy, particularly due to its efficacy and good tolerability. Visceral metastases should not be a criterion in favour of chemotherapy over hormonal therapy. Since they are well tolerated, aromatase inhibitors are recommended as first-line hormonal therapy in postmenopausal patients. However, tamoxifen remains an acceptable option. The results of the recent CONFIRM and FIRST clinical trials support the use of 500 mg fulvestrant every four weeks in patients in whom prior hormonal therapy failed.

Keywords: hormonal therapy, metastatic breast cancer, fulvestrant 500 mg.